The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers. by Lawn, W et al.
Nicotine & Tobacco Research, 2017, 1–10
doi:10.1093/ntr/ntx159
Original investigation
Received September 2, 2016; Editorial Decision June 29, 2017; Accepted July 12, 2017
© The Author 2017. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. 1
Original investigation
The Acute Effects of a Dopamine D3 Receptor 
Preferring Agonist on Motivation for Cigarettes 
in Dependent and Occasional Cigarette Smokers
Will Lawn PhD1, Tom P. Freeman PhD1,2, Katie East MSc2, Annie Gaule MSc1, 
Elizabeth R. Aston PhD6, Michael A. P. Bloomfield MD1,3,4, Ravi K. Das PhD1, 
Celia J. A. Morgan PhD1,5, H. Valerie Curran PhD1
1Clinical Psychopharmacology unit, University College London, Gower St, London, UK; 2Addictions Department, 
Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 3Psychiatric Imaging 
Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, London, UK; 4Division of 
Psychiatry, University College London, Maple House, London, UK; 5Department of Psychology, University of Exeter, 
Washington Singer Building, Perry Road, Exeter, UK; 6Center for Alcohol and Addiction Studies, Brown University 
School of Public Health, Providence, RI
Corresponding Author: Will Lawn, PhD, Clinical Psychopharmacology Unit, University College London, 
Gower St, London, WC1E 6BT. Telephone: 020 3108 3319; Fax: 020 7916 1989; E-mail: will.lawn@ucl.ac.uk
Abstract
Background: Dopaminergic functioning is thought to play critical roles in both motivation and 
addiction. There is preliminary evidence that dopamine agonists reduce the motivation for ciga-
rettes in smokers. However, the effects of pramipexole, a dopamine D3 receptor preferring agonist, 
have not been investigated. The aim of this study was to examine the effects of an acute dose of 
pramipexole on the motivation to earn cigarettes and nondrug rewards.
Methods: Twenty dependent and 20 occasional smokers received 0.5 mg pramipexole using a 
double-blind, placebo-controlled crossover design. Motivation for cigarettes and consummatory 
nondrug rewards was measured using the DReaM-Choice task, in which participants earned, and 
later “consumed,” cigarettes, music, and chocolate. Demand for cigarettes was measured using 
the Cigarette Purchase Task (CPT). Self-reported craving, withdrawal, and drug effects were also 
recorded.
Results: Dependent smokers chose (p < .001) and button-pressed for (p < .001) cigarettes more, 
and chose chocolate less (p < .001), than occasional smokers. Pramipexole did not affect the num-
ber of choices for or amount of button-pressing for any reward including cigarettes, which was 
supported by a Bayesian analysis. The dependent smokers had greater demand for cigarettes than 
occasional smokers across all CPT outcomes (ps < .021), apart from elasticity. Pramipexole did not 
affect demand for cigarettes, and this was supported by Bayesian analyses. Pramipexole produced 
greater subjective “feel drug” and “dislike drug” effects than placebo.
Conclusions: Dependent and occasional cigarette smokers differed in their motivation for ciga-
rettes but not for the nondrug rewards. Pramipexole did not acutely alter motivation for ciga-
rettes. These findings question the role of dopamine D3 receptors in cigarette-seeking behavior in 
dependent and occasional smokers.
Implications:  This study adds to the growing literature about cigarette versus nondrug reward pro-
cessing in nicotine dependence and the role of dopamine in cigarette-seeking behavior. Our results 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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suggest nicotine dependence is associated with a hypersensitivity to cigarette rewards but not a 
hyposensitivity to nondrug rewards. Furthermore, our results question the importance of dopa-
mine D3 receptors in motivational processing of cigarettes in occasional and dependent smokers.
Introduction
Mesocorticolimbic dopamine functioning putatively plays a critical 
role in the reinforcing effects of recreational drugs, including nicotine,1 
and the motivation for and learning about nondrug rewards.2–4 Over 
the past few decades, drug addiction has come to be conceptualized as 
a condition stemming from perturbations in the dopamine system.5–7 
More recently, theories of addiction have emphasized the apparent 
concomitant increase in sensitivity to drug reward and decrease in sen-
sitivity to nondrug reward.8 Dopamine is hypothesized to underpin 
this balance between drug and nondrug reward processing.9 Nicotine 
dependence has been associated with neuroadaptations in the dopa-
mine system,10,11 a neural insensitivity to monetary reward12,13 and an 
imbalance in the processing of cigarette and nondrug rewards.14–16
Manipulation of the dopamine system is thus a promising ave-
nue for the treatment of nicotine dependence. Indeed, bupropion, 
a dopamine and noradrenaline reuptake inhibitor, is efficacious in 
treating nicotine dependence. Bromocriptine, a dopamine D2 recep-
tor preferring agonist, has been shown to acutely reduce ad libitum 
cigarette smoking,17 while extended use of bromocriptine was also 
associated with reduced cigarette smoking.18
Pramipexole is a non-ergot-derived dopamine agonist that binds 
to dopamine D2, D3, and D4 receptors, with the greatest affinity for 
the D3 receptor.19 Pramipexole is primarily used to treat Parkinson’s 
disease due to its activation of dopamine receptors in the degenerat-
ing basal ganglia. At low doses (e.g., 0.5 mg oral in humans), prami-
pexole is thought to act primarily on presynaptic autoreceptors such 
that it has an inhibitory effect on phasic dopamine firing.20–22 This 
reduction in phasic firing could theoretically lessen craving and hence 
decrease motivation for cigarettes.23 Indeed, in nicotine-dependent 
individuals, 0.5 mg of pramipexole reduced attentional bias to ciga-
rette images24 while enhancing motivation for monetary reward.25
Aspects of both cigarette26,27 and nondrug reward processing16,28,29 
significantly predict the success of smokers who are attempting to 
quit. Therefore, pharmacological treatments for nicotine dependence 
that simultaneously reduce motivation for cigarettes and augment 
motivation for alternative, nondrug rewards may be particularly 
efficacious.
In this study, we examined whether a single low (0.5 mg oral) 
dose of pramipexole would reduce dependent and occasional 
cigarette smokers’ motivation for cigarettes. We utilized a newly 
designed task, the Drug Reward and Motivation-Choice (DReaM-
Choice) task,14 which measures motivation for both cigarette and 
consummatory nondrug rewards, using choices and repeated but-
ton-pressing. The DReaM-Choice has been shown to be sensitive to 
the level of nicotine dependence and acute nicotine abstinence. We 
also used a hypothetical cigarette purchase task (CPT),30 which is 
a behavioral economic task that asks participants how many ciga-
rettes they would buy for increasing amounts of money. Behavioral 
economics views addiction as a state in which the substance acquires 
higher value than alternative rewards; the CPT measures the rela-
tionship between cigarette consumption and cost, that is, demand 
for cigarettes. Purchase tasks are analogous to progressive ratio self-
administration tasks, but they are more efficient and have been used 
successfully in tobacco30 and marijuana31 users.
We hypothesized that:
1. Pramipexole would reduce motivation for cigarettes and increase 
motivation for nondrug rewards in the DReaM-Choice task.
2. Pramipexole would reduce demand for cigarettes in the CPT.
3. Compared to occasional smokers, dependent smokers would be 
more motivated for cigarettes on the DReaM-Choice task and 
exhibit greater demand for cigarettes in the CPT.
4. Pramipexole would have differential effects on the occasional 
and dependent smokers’ motivation to smoke cigarettes in both 
tasks. We did not hypothesize the direction of this interaction.
Methods
Design and Participants
A double-blind, placebo-controlled, crossover design with a between-
subjects factor of group (dependent and occasional) and a within-
subject factor of drug (placebo and pramipexole) was used. Twenty 
dependent (10 women) and 20 occasional (10 women) cigarette 
smokers took part in the study. A power analysis showed that a total 
sample size of 22 would be sufficient to detect a between-within inter-
action of medium effect size (f = 0.25) and a correlation between 
repeated measures of 0.7 (based on Lawn et al.14), with an α of 0.05 
and a power of 0.8. However, we proceeded with the larger total 
sample size of 40 as used previously with the DReaM-Choice task,14 
which gave us a power of 0.98 to detect an interaction with an effect 
size of f = 0.25. Having said that, if the correlation between repeated 
measures in this study was not as high as it was in the previous study 
(0.7), the power to detect the interaction would drop from 0.98.
Dependent smokers smoked on average ≥10 cigarettes/day and 
had a score of ≥5 on the Fagerstrom Test of Nicotine Dependence 
(FTND). Occasional smokers smoked on average 0.5–5 cigarettes 
per week and had an FTND score of 0.  More detailed eligibility 
criteria can be found in the Supplementary material. The experiment 
was approved by University College London ethics committee, and 
all participants gave informed consent.
Assessments
DReaM-Choice
The DReaM-Choice (Figure 1)14 task involves participants making 
a series of two-option choices between different rewards (cigarette, 
music, chocolate, and paper—a neutral commodity) and then work-
ing for the chosen option via repeated button-pressing. Points for 
each reward are accumulated throughout the task and are exchanged 
for real delivered rewards after the task has been completed, which 
can then be consumed in the laboratory.14 The Supplementary mate-
rials provide a detailed description of the updated version of the task.
In brief, the DReaM-Choice task measures two main outcomes: 
(1) the number of choices for each reward and (2) the average num-
ber of button-presses for each reward. Figure 1 depicts an example 
trial in which there is a choice between cigarette and chocolate, the 
cigarette is chosen, and then subsequently worked for.
After the task, participants received their delivered rewards and 
had 20 minutes to consume them. Every time they consumed 1 unit 
(¼ cigarette, 30s music, ½ chunk of chocolate) of a reward, they 
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reported their subjective liking (rated from −10 “extremely dislike” 
to +10 “extremely like”). However, we report only their subjective 
liking of the first “unit” of each reward consumed due to satiation 
effects.
Cigarette Purchase Task
The CPT30 assesses cigarette demand, or in other words, the rela-
tionship between cigarette consumption and cost.30 It is an analogue 
of a progressive ratio operant task, as consumption is investigated 
under progressively increasing financial cost. It is an established and 
well-validated task that is used to examine the behavioral economic 
concept of “demand” relating to cigarettes.30,35 In this version, par-
ticipants were asked how many cigarettes they would hypothetically 
buy for the next 3 hours at increasing prices.36 Participants were 
asked “How many cigarettes would you smoke if they were _____ 
each”. Prices included: £0 (free), 1p, 2p, 5p, 10p, 15p, 20p, 25p, 
30p, 35p, 40p, 45p, 50p, 60p, 70p, 80p, 90p, £1, £2, £3, £4, and 
£5 and were presented in that order. The CPT generates five indices 
of cigarette demand: breakpoint (cost suppressing consumption to 
zero), intensity (amount of drug consumed at zero cost), Omax (peak 
expenditure), Pmax (price at maximum expenditure), and elasticity 
(the slope of the demand curve); see Supplementary material for 
more details.
Self-Rated Assessments
State Measures
Tobacco Craving Questionnaire-Short Form (TCQ-SF)
This craving scale37 consists of 12 items that are rated “right now” 
from 1 (strongly disagree) to 7 (strongly agree). There are four 
subscales: emotionality, expectancy, compulsivity, and purposeful-
ness. Higher scores reflect greater tobacco craving.
Mood and physical symptoms scale (MPSS)
This scale38 consists of 7 items that assess nicotine withdrawal symp-
toms. Five items were rated “right now” from 1 (not at all) to 5 
(extremely): “depression,” “irritability,” “restlessness,” “hunger,” 
and “poor concentration.” Two items were rated “in the past two 
hours”: “how much have you felt the urge to smoke?” from 0 (not at 
all) to 5 (all the time) and “how strong have these urges been?” from 
0 (no urges) to 5 (extremely strong). Higher scores reflect greater 
withdrawal symptom severity.
Drug Effects Questionnaire (DEQ)
This assessment39 comprised 5 visual analogue scales (VAS) rated 
according to how the participant feels “right now” from 0 mm (“not 
at all”) to 100 mm (“extremely”): (1) “do you feel a drug effect”; (2) 
“are you high”; (3) “do you dislike any of the effects”; (4) “do you 
like any of the effects,” and (5) “would you like more”.
Nausea and Drowsiness
Participants reported how nauseous and how drowsy they were 
from 0 “not at all” to 10 “extremely.”
Time Since Last Smoked
Participants were asked whether they had smoked tobacco on the 
day of testing and the day before testing. If the answer to either of 
these questions was yes, they stated how long ago they last smoked 
tobacco.
Figure 1. (A) Diagrammatic representation of a single trial of the DReaM-Choice Task. It was designed to determine (1) the number of choices for each reward, 
which indexes “relative preference” and (2) the average number of button-presses for each reward, which indexes motivation. During the “choice stage”, the 
cues were presented and a choice was made with button F (left option) or J (right option; unlimited time); during the “anticipate stage 1”, the word of the reward, 
for example, “cigarette,” was shown (0.5s); during the “anticipate stage 2,” a small version of the cue was shown (4s); during the “respond stage,” the spacebar 
was pressed as many times as desired with the nondominant little finger in 7s,32 in order to win points for the chosen reward; during the “feedback stage,” 
feedback concerning the amount of points won was provided for 1s. Each of the 6 possible choices were presented 4 times in three blocks, making a total of 72 
trials, with trial order pseudo-randomized and left/right cue position counterbalanced. (B) The cues used in the DReaM-Choice task to represent each reward. 
From left to right: cigarette, chocolate, music, and paper. The “delivered rewards” which were actually given to participants to consume after the DReaM-Choice 
task finished were Malboro Gold cigarettes (tar 6 mg and nicotine 0.5 mg), Cadbury’s Dairy Milk chocolate, individually chosen music,33 and pieces (~2cm2) of 
lined paper. Paper was included as a control commodity to demonstrate that the rewards were motivating relative to a control commodity.14,34
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Trait Measures
These measures assessed depression, tobacco/nicotine dependence, 
history of drug use, and anhedonia. A  full description of the trait 
measures used can be found in the Supplementary material.
Procedure
Participants were screened on the telephone to determine if they met 
the eligibility criteria. Eligible participants attended two 3.5-hour ses-
sions separated by a washout period lasting between 7 and 25 days 
(mean = 9, SD = 4.4). Participants were told to smoke “normally” 
before the experiment; they were allowed to smoke (or not) before 
they arrived, depending on what was normal for them. Participants 
were also asked to fast for an hour beforehand and to avoid driv-
ing or operating heavy machinery on the day of testing. First, par-
ticipants provided a carbon monoxide (CO) reading and completed 
the state questionnaires (excluding the DEQ). Pramipexole (0.5mg; 
peak plasma levels 1-3 h)40 or matched placebo (lactose powder) 
was then orally administered. Based on previous research,25,41 30 mg 
of the peripheral dopamine D2 antagonist domperidone was orally 
administered on both sessions to reduce unwanted side effects such 
as nausea. Previous research suggests minimal central effects of dom-
peridone,42 as it cannot cross the blood–brain barrier.43 Therefore, we 
assumed domperidone would not affect reward processing, and pre-
vious researchers have made this assumption too.24,25,41 The nausea 
experienced by the participants had domperidone not been adminis-
tered would have made the experiment unfeasible. Immediately after 
drug administration, participants completed half of the trait ques-
tionnaires, which were split across the two sessions. Testing began 
90 minutes postdrug administration. Assessments were conducted 
in the following order: state questionnaires (90 minutes), CPT (100 
minutes), other tasks that will be described elsewhere (105 minutes), 
DReaM-Choice task (145 minutes), reward consumption (175 min-
utes), and state questionnaires (195 minutes). Given the participants 
could have smoked just before taking part in the experiment, the 
minimum length of nicotine abstinence before the CPT was therefore 
approximately 1 hour 40 minutes, and the minimum length of nico-
tine abstinence before the DReaM-Choice task was approximately 2 
hours 25 minutes. Smoking was not permitted until the consumption 
stage of the experiment. Participants were reimbursed £7.50/h.
Statistical Analyses
All data were analyzed using IBM Statistical Package for Social 
Sciences (IBM SPSS version 22)  and Graphpad Prism 6, for the 
Cigarette Purchase Task data.
The majority of data were analyzed using the general linear 
model. Where residuals were not normally distributed or the group 
variances were not homogenous, nonparametric tests were used 
when available and appropriate. In repeated-measures analysis of 
variance [ANOVA], when sphericity was violated, the Greenhouse-
Geisser correction was used, and corrected degrees of freedom are 
reported. In order to explore significant interactions, a Bonferonni 
correction was applied to post hoc comparisons via the syntax in 
SPSS. Drug order was included in all of the ANOVAs to determine if 
its presence affected the pattern of results. It did not, so the results 
are reported without drug order included. Given Beck Depression 
Inventory (BDI) scores differed between groups, we included this as 
a covariate after each analysis. In order to evaluate evidence in favor 
of null hypotheses, scaled Jeffreys-Zellner-Siow (JZS) Bayes factors 
were calculated using an online calculator (http://pcl.missouri.edu/
bayesfactor). We used a scaled-information prior of r = 1, which is 
the default value recommended.44
A detailed description of the statistical analyses used for each set 
of data can be found in Supplementary material.
Results
Demographics 
The dependent smokers and occasional smokers had similar aver-
age ages of 24.4 (SD = 6.8) and 22.6 (SD = 3.79), respectively. 
The dependent smokers had greater dependence than the occa-
sional smokers on the FTND (5.7 vs. 0, U38 = 0.00, p < .001) and 
the Cigarette Dependence Scale (CDS; 18.5 vs. 7.7, t37=11.923, p < 
.001). The dependent smokers smoked more cigarettes per day and 
week (16.5 vs. 0.5, U38 = 0.00, p < .001), started smoking at an earlier 
age (13.4 vs. 15.0, t38 = 2.504, p = .017) and reported greater subjec-
tive liking, in general, of smoking a cigarette (8.2 vs. 5.2, t37 = 4.687, 
p < .001; Supplementary Tables A and B ) compared with the occa-
sional smokers. There was no evidence that the groups differed on 
any nonsmoking demographic variables apart from BDI, on which 
dependent smokers (10.80, SD = 7.50) had a greater score than occa-
sional smokers (6.26, SD = 4.58; t37=2.265, p = .029.
State Measures
Relative to placebo, pramipexole increased feelings of “feel drug” 
and “dislike drug” and decreased feelings of “want more drug.” See 
Supplementary material for the full drug effects questionnaire results.
TCQ 
On each subscale and the total TCQ score (Table 1), there was an 
interaction between group and time, and main effects of both group 
and time. Dependent smokers, compared with occasional smokers, 
had greater craving on each subscale. Craving scores increased from 
predrug to postdrug and decreased from postdrug to postconsump-
tion in dependent smokers, whereas craving scores stayed similar 
between predrug and postdrug and decreased from post-drug to 
post-consumption in occasional smokers. There was a main effect of 
drug on the compulsivity and purposefulness subscales, with greater 
scores on the pramipexole session than the placebo session.
MPSS 
“Depressed” scores decreased as the experiment progressed while 
“hungry,” “poor concentration” and “time spent with urges” 
increased as the experiment progressed (Supplementary Table C). The 
dependent smokers, compared with the occasional smokers, reported 
greater “time spent with urges” and “strength of urges to smoke.” 
There was a main effect of drug on “strength of urges to smoke,” with 
greater scores on the pramipexole session than the placebo session.
Nausea and Drowsiness
There were Drug × Time interactions for both nausea (F2, 76 = 5.863, 
p = .004, η2p = 0.134) and drowsiness (F2, 76 = 9.699, p < .001, η
2
p = 
0.203). Exploration of the interactions showed that at postconsump-
tion, for nausea, pramipexole led to higher ratings than placebo (t38 
= 2.571, p = .014, mean difference = 0.900) and at postconsump-
tion, for drowsiness, pramipexole led to higher ratings than placebo 
(t38=4.695, p < .001, mean difference = 2.000).
Time Since Last Smoked
On the placebo condition, all dependent smokers had smoked either 
on the day of testing (n = 18) or the day before (n = 2), and the mean 
time since last cigarette (relative to the start of the experiment) was 
87.90 (SD = 217.94) minutes. On the placebo condition, six of the 
occasional smokers had smoked either on the day of testing (n = 3) 
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or the day before (n = 3). Of those six, the mean time since last ciga-
rette was 501.83 (SD = 556.35) minutes.
On the pramipexole condition, all dependent smokers had 
smoked on the day of testing, and the mean time since last cigarette 
was 29.30 (SD = 37.07) minutes. On the pramipexole condition, 
seven of the occasional smokers had smoked either on the day of 
testing (n = 1) or the day before (n = 6). Of those seven, the mean 
time since last cigarette was 915.05 (SD = 258.33) minutes.
The DReaM-Choice task was completed approximately 2 hours 25 
minutes after the start of the experiment, so each participant’s nicotine 
abstinence was equal to 2 hours 25 minutes + their time since last smoked.
Neither group significantly differed in their time since last ciga-
rette between placebo and pramipexole conditions. However, there 
was a main effect of group such that the dependent smokers had 
smoked more recently than the occasional smokers (F1, 24 = 55.972, 
p < .001, η2p = .700).
DReaM-Choice task
Choices 
One occasional smoker’s data was missing due to a computer error 
(Figure  2a). A  three-way ANOVA with a between-subjects fac-
tor of group and within-subjects factors of drug and reward was 
conducted. There was an interaction between group and reward 
(F2.430, 89.927 = 21.009, p < .001, η
2
p = .362) and a main effect of reward 
(F2.430, 89.927 = 55.883, p < .001, η
2
p = .602). Exploration of the Group × 
Reward interaction showed that dependent smokers chose cigarettes 
more (t37 = 7.259, p < .001, mean difference=15.737, 95% confi-
dence interval [CI]: 11.344 to 20.129) and chocolate less (t37=4.702, 
p < .001, mean difference = 12.366, 95% CI: 7.038 to 17.694) than 
occasional smokers.
There was no three-way interaction (F2.412, 89.251 = 0.502, p = .660, 
η2p = .013) and no interaction between drug and reward (F2.412, 89.251 = 
0.550, p = .612, η2p = .015) and no main effect of drug (F1, 37= .769, 
p = .386, η2p=0.020). Covarying for BDI had no effect.
For the effect pramipexole had on cigarette choices, within the 
dependent smokers, the Bayesian analysis showed that the null 
hypothesis was about 6 times more likely than the alternative hypoth-
esis (JZS Bayes factor = 5.86), providing evidence that pramipexole 
did not affect their number of cigarette choices. Within the occa-
sional smokers, the Bayesian analysis showed that the null hypoth-
esis was about 6 times more likely than the alternative hypothesis 
(JZS Bayes factor = 5.63), providing evidence that pramipexole did 
not affect their number of cigarette choices.
Average Number of Button-Presses 
One occasional smoker’s data was missing due to a computer 
error (Figure  2b). There were no differences between the groups 
Figure 2. Group means for (A) The number of choices for each reward type and (B) the average number of button-presses for each reward type, in the DReaM-
Choice, for dependent and occasional smokers on the placebo and pramipexole sessions. Error bars show standard error.
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or sessions in baseline button-pressing speed, so analysis continued 
without including this as a covariate. A  three-way ANOVA with 
a between-subjects factor of group and within-subjects factors of 
drug and reward was conducted. There was an interaction between 
group and reward (F3, 111 = 6.999, p < .001, η
2
p = .159) and a main 
effect of reward (F3, 111 = 35.373, p < .001, η
2
p = 0.489). Exploration 
of the Group × Reward interaction showed that the dependent 
smokers pressed for cigarettes more (t37=3.663, p < .001, mean 
difference=11.613, 95% CI: 5.189 to 18.036) than the occasional 
smokers. There was no three-way interaction (F3, 111=35.373, p < 
.001, η2p=0.489), no interaction between drug and reward (F2.229, 82.461 
= .976, p = .389, η2p=0.026), and no main effect of drug (F1, 37 = .348, 
p = .559, η2p=0.009). Covarying for BDI had no effect.
For the effect pramipexole had on button-pressing for cigarettes, 
within the dependent smokers, the Bayesian analysis showed that 
the null hypothesis was about 4 times more likely than the alterna-
tive hypothesis (JZS Bayes factor = 3.58), providing evidence that 
pramipexole did not affect button-pressing for cigarettes. Within 
the occasional smokers, the Bayesian analysis showed that the 
null hypothesis was about 3 times more likely than the alternative 
hypothesis (JZS Bayes factor = 3.36), providing evidence that prami-
pexole did not affect button-pressing for cigarettes.
See Supplementary material for the “time taken to choose a 
reward” results.
Liking of First Reward Unit Consumed 
There was an interaction between group and reward (F2, 130.476 = 
4.457, p = .013, η2p=0.064) and a main effect of group (F1, 41.759 
= 6.086, p = .018, η2p = 0.226), with overall liking higher in the 
dependent smokers than the occasional smokers (Supplementary 
Figure A). The Group × Reward interaction was explored by 
conducting mixed effects models within each reward separately. 
Dependent smokers liked cigarettes more than occasional smokers 
(F1, 26.073 = 19.738, p < .001, η
2
p=0.431), but there were no differ-
ences for music (F1, 28.799=1.567, p = .221, η
2
p=0.0516) or chocolate 
(F1, 32.330 = 0.140, p = .710, η
2
p=0.004). There was a trend main 
effect of drug with liking ratings marginally higher following 
pramipexole compared with placebo (F1, 122.249 = 3.175, p = .077, 
η2p = 0.0253) but no Drug × Reward interaction (F2, 121.737 = 0.388, 
p = .679, η2p = .006).
CPT 
One dependent smoker and three occasional smokers were excluded 
for stating they would buy the same amount of cigarettes for every 
price (Figure 3). Elasticity for an additional two occasional smokers 
could not be calculated by GraphPad Prism 6 due to an unsuitable 
range of data points. Breakpoint, intensity, Omax, and Pmax were all 
log10 transformed to improve the normality of their distributions 
and their residuals’ distributions. Correlations between the indices 
of demand can be seen in Table E of the Supplementary material. 
There were frequently high associations between them, as has been 
found in previous research.
A two-way ANOVA with a between-subjects factor of group and 
a within-subjects factor of drug was conducted for each CPT out-
come variable. There was a main effect of group for breakpoint (F1, 
32=21.764, p < .001, η
2
p=0.404), intensity (F1, 32=35.367, p < .001, 
η2p=0.525), Omax (F1, 31=25.147, p < .001, η
2
p=0.448), and Pmax (F1, 
31=18.740, p < .001, η
2
p=0.377). For all of these outcomes, depend-
ent smokers had greater values than occasional smokers. There was 
no main effect of drug and no interaction between drug and group 
on any CPT metric (see Supplementary Table D).
Adding BDI as a covariate into the models showed that BDI did 
not interact with the drug effects; however, higher BDI levels were 
associated with greater demand for cigarettes (see Supplementary 
material).
For the effect of pramipexole on CPT metrics, within dependent 
smokers, the Bayesian analyses showed that the null hypotheses 
were more likely than the alternative hypotheses for breakpoint, 
intensity, Omax, Pmax, and elasticity with JZS Bayes factors of 5.56, 
2.14, 4.69, 1.08, and 2.39, respectively. Within the occasional 
smokers, the Bayesian analyses showed that null hypotheses were 
more likely than the alternative hypotheses for breakpoint, inten-
sity, Omax, Pmax, and elasticity with JZS Bayes factors of 5.26, 4.62, 
2.98, 4.24, and 1.58.
Figure 3. Cigarette demand curve from the Cigarette Purchase Task (CPT) for dependent and occasional smokers on the placebo and pramipexole sessions. 
Error bars show standard error. DepPlac = Dependent smokers on placebo; OccPlac = Occasional smokers on placebo; DepPram = Dependent smokers on 
pramipexole; OccPram = Occasional smokers on pramipexole.
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Correlations
Within the occasional smokers, subjective ratings of liking cigarettes 
in general predicted behavior on the DReaM-Choice task. However, 
this was not the case in the dependent smokers. See Supplementary 
material for full results.
Fidelity of the Blind
The distribution of drug guesses (whether the participant was on 
placebo or pramipexole) was marginally different from that of 
chance as determined by the McNemar test (p = .052), suggesting 
there was some evidence that participants could tell what drug they 
had been given.
Discussion
To the authors’ knowledge, this is the first study to examine whether 
pramipexole acutely influences motivation for real cigarettes. In 
dependent and occasional cigarette smokers, a single oral 0.5 mg dose 
of pramipexole did not affect the relative preference for, motivation 
for and liking of cigarettes in the DReaM-Choice task. Moreover, 
there was no evidence that pramipexole affected demand for ciga-
rettes in the CPT or self-reported craving or withdrawal symptoms. 
Nor was there evidence that pramipexole influenced responding for 
the consummatory nondrug rewards in the DReaM-Choice task. 
Bayesian analyses, conducted within each group separately, showed 
there was evidence in favor of the null hypotheses that pramipex-
ole did not affect motivation for cigarettes or cigarette demand in 
the CPT. Furthermore, pramipexole did not have different effects 
on occasional and dependent smokers’ motivation for cigarettes. In 
support of previous research,14 dependent smokers exhibited greater 
motivation for cigarettes than occasional smokers, while there was 
no evidence that dependent smokers were less motivated to receive 
chocolate or music.
Pramipexole
In terms of pramipexole affecting choices, button-pressing, and 
demand for cigarettes, we found nonsignificant results, mostly 
small effect sizes and evidence from Bayesian analyses in favor of 
the null hypotheses. Our findings therefore question the role of the 
D2-subfamily of dopamine receptors, especially the D3 receptor in 
the motivation to smoke cigarettes. Given bromocriptine reduced ad 
libitum smoking in humans,17 D2-preferring agonists may be supe-
rior to D3-preferring agonists (pramipexole) in disrupting cigarette 
processing. However, their results could be partially due to large 
increases in nausea, rather than central dopamine receptor agonism. 
If nausea simply reduces cigarette smoking, the coadministration 
of domperidone may have dampened the effects of pramipexole. 
Interestingly, although we coadministered domperidone, the prami-
pexole condition did lead to higher ratings of nausea and drowsi-
ness at postconsumption, so domperidone did not fully eradicate the 
emetic effects of pramipexole.
More generally, the focus on dopamine in addiction, particularly 
nonstimulant addiction, may be overstated.5 For instance, acutely 
administered nicotine has sometimes failed to provoke dopamine 
release in the striatum,45,46 and an unchanged striatal D2/D3 recep-
tor density in cigarette smokers has been reported.47 Despite some 
positive findings concerning bromocriptine, other dopamine ago-
nists and antagonists have failed to show effects on craving for ciga-
rettes.23 Our null results lend support to the general hypothesis that 
nicotine addiction is more complex, in a neurobiological sense, than 
simply a dysfunctioning dopamine system.
Alternatively, it may be that chronic, rather than acute, admin-
istration of pramipexole is needed in order to more substantially 
manipulate the dopamine system such that motivation to smoke is 
lowered. Indeed, bupropion, an approved drug for aiding smoking 
cessation can increase smoking when given acutely48 but reduces 
smoking when given chronically.49 Importantly, pramipexole may 
have different effects in cigarette smokers who are motivated to quit 
from those who are not, like bupropion and nicotine replacement 
therapy.50
Previously, pramipexole (at this dose) has been shown to reduce 
the strength of urges to smoke.24 In contrast, craving in this study 
appeared to be greater during the pramipexole session compared 
with the placebo session (on two subscales of the TCQ-SF and 
the “strength of urges” subscale of the MPSS). However, there 
were no Drug ×Time interactions, and these effects appeared to be 
driven by seemingly random baseline differences (see Table 1 and 
Supplementary Table C). Hence, our results suggest that pramipex-
ole neither reduced nor enhanced craving for cigarettes.
Pramipexole did not affect relative preference for, motivation 
for or liking of the consummatory nondrug rewards, music, and 
chocolate. Given its promotivational acute,25 we had hoped prami-
pexole would enhance nondrug reward processing, while impairing 
cigarette reward processing.24,25 This differential profile of drug and 
nondrug reward processing effects may have the most therapeutic 
benefits.16,28 However, not only did pramipexole fail to significantly 
alter processing of cigarette reward, it also failed to alter reward 
processing of the consummatory nondrug rewards.
Group differences
In terms of group differences, the dependent smokers demon-
strated hypersensitivity to cigarettes compared with the occasional 
smokers. The dependent smokers chose cigarettes more frequently, 
worked harder for them during the button-pressing stage and 
reported greater subjective liking when they consumed cigarettes. 
This replicates a previous comparison between these groups on the 
DReaM-Choice task.14 Despite augmented motivation for drugs 
being a hallmark of addiction, previous laboratory-based tests of 
cigarette self-administration have sometimes failed to differentiate 
addicted and nonaddicted smokers.15,51 Therefore, these data from 
the DReaM-Choice reveal that enhanced motivated responding 
for cigarettes in dependent versus occasional smokers can be reli-
ably detected in the laboratory. Moreover, as would be expected, 
the forced period of nicotine abstinence during the experiment 
enhanced craving only in the dependent smokers, but not the occa-
sional smokers, who would be used to periods much longer than 
this without smoking.
There was no evidence that dependent smokers were less moti-
vated for chocolate or music than occasional smokers, as measured 
by button-pressing. This corroborates previous research14,52 that nic-
otine-dependent smokers do not appear to be amotivated for non-
drug rewards following ad libitum smoking or short (approximately 
2 hours 25 minutes in this study) nicotine abstinence. Whether or 
not more substantial nicotine abstinence (12-24 hours) produces 
nondrug reward processing deficits remains contentious.14,15,52,53
Strengths and limitations
Key strengths of this study include the placebo-controlled, double-
blind, crossover design; the relatively large sample size (n = 40), 
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compared with other acute pramipexole studies20,24; the well-matched 
groups; the range of metrics we used to assess motivation to smoke 
cigarettes; and the comparison of real cigarettes with real nondrug 
rewards in the DReaM-Choice task. Another strength is that results 
from the DReaM-Choice task and the CPT dovetailed to demon-
strate that pramipexole had no significant effect on motivation to 
smoke cigarettes. Moreover, the associations between performance 
on the DReaM-Choice task and the CPT demonstrate the DReaM-
Choice task’s validity. A methodological improvement would have 
been the measurement of biological variables, such as pramipexole 
plasma levels40 so that the ability of the drug to enter the blood could 
have been verified. Future research should also investigate the effects 
of different doses of pramipexole on motivational processing.
Summary
In conclusion, we found no evidence to suggest that an acute, 
low dose of pramipexole reduces motivation for cigarettes 
or redresses the imbalance of cigarette and non-drug reward 
processing in dependent cigarette smokers. Following a short 
period of nicotine abstinence (2 hours 25 minutes), dependent 
smokers appeared to be more motivated for cigarettes but no 
less motivated for consummatory nondrug rewards than occa-
sional smokers. These findings may question the role of the 
D2-subfamily of dopamine receptors, especially the D3 receptor, 
in cigarette-seeking behavior in both dependent and occasional 
smokers; however, further pharmacological and imaging research 
is needed to fully understand what roles these receptors play in 
nicotine dependence.
Supplementary Material
Supplementary data are available at Nicotine and Tobacco Research online.
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